BRAIN-AF Study Receives Canadian Institutes of Health Research Grant

 The BRAIN-AF study

The study is that the first within the world to research the consequences of fibrillation on cognitive decline in young patients up to age 65

MONTREAL, March 16, 2021 (News) — The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research. Seeking to raised understand the consequences of disorder on the cognitive decline of the brain, the study is going to be ready to recruit participants remotely because of this funding.

BRAIN-AF is studying a standard cardiac rhythm disorder called fibrillation (AF). this is often the primary study within the world to research the consequences of fibrillation on cognitive decline in young patients up to age 65. “We hypothesize that cardiac micro clots damage the brains of young patients with fibrillation,” says Dr Lena Rivard, a cardiologist specializing in electrophysiology at the MHI, and therefore the PI of the BRAIN-AF study launched in 2015 together with her colleagues, Drs. Denis Roy and Paul Khairy.

Although anticoagulant therapy is indicated for older people (over 65 years old) or those who present a further risk factor (such as a high vital sign, diabetes, coronary failure, or a history of stroke) with fibrillation, it's limitations for younger people living with the condition due to the danger of bleeding related to the medication. By investigating an anticoagulant called rivaroxaban, the research team hopes to scale back the danger of cognitive decline within the brain and stroke in younger patients. If this new therapy proves effective, it may benefit an estimated 125,000 people in Canada.

“We believe that this anticoagulant treatment will prevent the onset and progression of cognitive impairment, in other words, by treating a cardiac rhythm disorder, we might be developing a replacement approach to preventing amnesia and dementia,” says Dr Lena Rivard.

👉Click Here and Check Our Recommended Weight Loss Supplement 

BRAIN-AF may be a double-blinded, placebo-controlled clinical study approved by Health Canada. The pilot phase of the study of 500 patients shows an honest safety profile and therefore the preliminary results also show that the cognitive decline in these patients would be greater than expected. Almost 40% of the patients needed (more than 800 patients) were recruited in 44 centres in Canada, of which about 20 are in Quebec.

Atrial Fibrillation and Cognitive DeclineAtrial fibrillation affects about 200,000 people in Canada. This disorder affects the 2 upper chambers of the guts called the atria. The atria are the receiving chambers of the guts that ensure, through regular electrical signals, the efficient blood flow to the heart’s ventricles then to the remainder of the body. In fibrillation, the electrical signals are rapid, irregular and disorganized, reducing the heart’s efficiency in pumping blood.

If fibrillation is left untreated, it can cause blood clots to make within the atria. These can cause strokes and consistent with the ICM researchers, they'll be liable for memory problems and dementia. In fact, consistent with the planet Health Organization (WHO), dementia affects quite 50 million people. In Canada alone, quite 747,000 seniors are suffering from this condition.

About the Montreal Heart InstituteFounded in 1954, the Montreal Heart Institute constantly strives for the very best standards of excellence within the cardiovascular field through its leadership in clinical and fundamental research, ultra-specialized care, professional training, and prevention. it's home to Canada’s largest cardiology research centre, cardiovascular prevention centre, and cardiovascular genetics centre. The Institute is affiliated with the Université de Montréal and has quite 2,000 employees, including 245 physicians and quite 85 researchers. icm-mhi.org

👉Click Here and Check Our Recommended Fat Loss Supplement